For people with unresectable Stage 3 non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent chemoradiation therapy (cCRT). See Full Indication »
When Stage 3 non-small cell lung cancer (NSCLC) cannot be removed by surgery, the first step in treatment is usually a combination of chemotherapy and radiation, called “chemoradiation therapy” or “CRT.” These can be given at the same time (concurrent) or one after the other (sequential). This usually lasts 6 to 7 weeks. The two treatments work in different ways to attack cancer.
attacks all fast-growing cells, including cancer cells.
targets DNA in cancer cells to keep them from growing.
If you are currently going through or have recently completed CRT, it’s important to continue working with your doctor to be prepared for what’s next. One study showed that within a year of receiving CRT, up to 89% of people progressed to Stage 4 NSCLC.
With no approved treatment options after CRT to help delay cancer progression, the only option for patients was to have regular scans to check for progression.
Receiving IMFINZI after CRT may help people keep fighting their Stage 3 lung cancer.
*For patients whose disease has not progressed after chemotherapy that contains platinum given at the same time as radiation therapy.
IMFINZI is a medicine that may treat a type of cancer in the bladder and urinary tract or certain types of lung cancer by working with your immune system.
IMFINZI can cause your immune system to attack normal organs and tissues and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death.
IMFINZI® (durvalumab) is a prescription medicine used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC). IMFINZI may be used when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same time as radiation therapy.
It is not known if IMFINZI is safe and effective in children.
Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with IMFINZI. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may delay or completely stop treatment with IMFINZI if you have severe side effects.
Before you receive IMFINZI, tell your healthcare provider about all of your medical conditions, including if you have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus; have had an organ transplant; have lung or breathing problems; have liver problems; or are being treated for an infection.
If you are pregnant or plan to become pregnant, tell your healthcare provider. IMFINZI can harm your unborn baby. If you are able to become pregnant, you should use an effective method of birth control during your treatment and for at least 3 months after the last dose of IMFINZI. Talk to your healthcare provider about which birth control methods to use. Tell your healthcare provider right away if you become pregnant during treatment with IMFINZI.
If you are breastfeeding or plan to breastfeed, tell your healthcare provider. It is not known if IMFINZI passes into breast milk. Do not breastfeed during treatment with IMFINZI and for at least 3 months after the last dose of IMFINZI.
Tell your healthcare provider about all the medicines you take. This includes prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects in people with non-small cell lung cancer (NSCLC) include cough, feeling tired, inflammation in the lungs (pneumonitis), upper respiratory tract infections, shortness of breath, and rash.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of IMFINZI. Ask your healthcare provider or pharmacist for more information.
Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
You may report side effects related to AstraZeneca products by clicking here.
IMFINZI® (durvalumab) is a prescription medicine used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC). IMFINZI may be used when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same time as radiation therapy.
It is not known if IMFINZI is safe and effective in children.
Please see complete Prescribing Information, including Patient Information (Medication Guide).
IMFINZI is a medicine that may treat a type of lung cancer by working with your immune system.
